 |
Abstract: ASN Annual Meeting -- San Francisco |
Dreisbach AW, Rice JC, Japa S, et al.
Salt Loading Increases Urinary Excretion of Linoleic Acid Diols and Triols.
ASN Annual Meeting -- San Francisco
J Am Soc Nephrol (Nov) 18:629A 2007
INTRODUCTION: Increased dietary intake of linoleic acid (LA) has been shown in clinical studies to reduce systolic blood pressure and increase sodium excretion. We studied the effect of salt loading on the excretion of LA diols and triols to investigate whether LA is associated with salt handling by the kidney in human subjects.
METHODS: 12 healthy subjects from the New Orleans population (pre-Katrina) were admitted to the Tulane-LSU GCRC after a 5-day outpatient lead in phase: 160 mmole sodium Na diet. On inpatient Day 1 (D1) the subjects were maintained on 160 mmole Na diet and a 24 hr urine was collected for the LA diols and triols: 9,10- DiHOME, 12,13-DiHOME, 9,10,13-TriHOME, and 9,12,13-TriHOME. On D2 the theyreceived 2 L of NS IV /4hr and (total 460 mmole Na)(Two 12 hr urine collections). On D3 three 40 mg oral doses of furosemide (10 mmole Na diet). Two 12 hr urine collection to D4 (10 mmole Na diet). The urinary LA metabolites were measured by HPLC-tandem qaudrapule mass spectroscopy.
RESULTS: The urinary excretion LA diols and triols increased significantly during day of the intravenous salt loading when the compared to the salt-depleted periods and Day 1 (Table).
CONCLUSIONS: Salt loading increase the urinary excretion of LA diols and triols which may inhibit tubular sodium reabsorption thereby assisting the excretion of the sodium load.
Urinary Exretion of LA Metabolites nmole/gC/hr Time Day 1 High Salt Day 2-2.5 IV NS Day 2.5-3 High Na Day 3.5-4 Low Na Day 4-4.5 Low Na 9,10-DIHOME 5.18 +/- 3.41 17.6 +/- 10.8 14.6+/-9.17 5.94 +/- 4.32 8.30 +/- 7.01 12,13-DIHOME 0.38 +/- 0.29 1.36 +/- 1.05 0.94 +/- 0.59 0.18 +/- 0.18 0.26 +/- 0.21 9,10,13-TRIHOME 0.21 +/- 0.16 0.67 +/- 0.35 0.63+/- 0.29 0.23 +/- 0.20 0.19 +/- 0.20 9,12,13-TRIHOME 2.78 +/- 2.81 7.95 +/- 9.45 4.99 +/- 5.20 1.08 +/- 2.22 0.51 +/- 0.44 Repeated Measures ANOVA- see text The poster for this abstract is available for viewing. YOU MUST SIGN IN FIRST at the ASN Posters2View website: (you need to type in a separate username and password of your choosing). If you are not signed in, the direct link to the poster below will not work!
Once signed in, you can access the poster for this abstract directly at this link.
Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.
The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.
To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.
In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.
| Related Folders: |
|
|
